← Back to Screener
AC Immune SA (ACIU)
Price$2.98
Favorite Metrics
Price vs S&P 500 (26W)-23.96%
Price vs S&P 500 (4W)-3.88%
Market Capitalization$389.09M
All Metrics
P/CF (Annual)3.38x
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)3.38x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.88%
Cash Flow / Share (Quarterly)$-0.88
Price vs S&P 500 (YTD)-8.28%
Net Profit Margin (TTM)-1971.70%
EPS (TTM)$-0.90
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-0.90
Revenue Growth (5Y)-25.34%
EPS (Annual)$-0.90
ROI (Annual)-142.53%
Net Profit Margin (5Y Avg)-948.37%
Cash / Share (Quarterly)$1.15
Revenue Growth QoQ (YoY)-70.27%
ROA (Last FY)-45.67%
Revenue Growth TTM (YoY)-86.92%
EBITD / Share (TTM)$-0.85
ROE (5Y Avg)-61.88%
Operating Margin (TTM)-1940.05%
Cash Flow / Share (Annual)$-0.88
P/B Ratio5.28x
P/B Ratio (Quarterly)5.41x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)60.11x
Net Interest Coverage (TTM)-61.40x
ROA (TTM)-38.75%
EV / EBITDA (TTM)4.41x
EPS Incl Extra (Annual)$-0.90
Current Ratio (Annual)1.02x
Quick Ratio (Quarterly)0.98x
3-Month Avg Trading Volume0.58M
52-Week Price Return100.67%
EV / Free Cash Flow (Annual)3.05x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.15
P/S Ratio (Annual)66.34x
Asset Turnover (Annual)0.02x
52-Week High$4.00
Operating Margin (5Y Avg)-941.52%
EPS Excl Extra (Annual)$-0.90
CapEx CAGR (5Y)-12.05%
Tangible BV CAGR (5Y)0.30%
26-Week Price Return-15.21%
Quick Ratio (Annual)0.98x
13-Week Price Return-17.98%
Total Debt / Equity (Annual)0.10x
Current Ratio (Quarterly)1.02x
Enterprise Value$275.523
Revenue / Share Growth (5Y)-30.20%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-31.83%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1971.65%
Cash / Share (Annual)$1.15
3-Month Return Std Dev69.47%
Net Income / Employee (TTM)$-1
ROE (Last FY)-156.95%
Net Interest Coverage (Annual)-3.40x
EPS Basic Excl Extra (Annual)$-0.90
P/FCF (TTM)2.98x
Receivables Turnover (TTM)4.90x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-0.90
Receivables Turnover (Annual)4.90x
ROI (TTM)-95.15%
P/S Ratio (TTM)66.34x
Pretax Margin (5Y Avg)-947.84%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.79
Free OCF CAGR (5Y)4.12%
Price vs S&P 500 (52W)65.57%
Year-to-Date Return-4.14%
5-Day Price Return-8.79%
EPS Normalized (Annual)$-0.90
ROA (5Y Avg)-32.68%
Net Profit Margin (Annual)-1971.65%
Month-to-Date Return9.45%
Cash Flow / Share (TTM)$-0.89
EBITD / Share (Annual)$-0.85
Operating Margin (Annual)-1940.05%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-58.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.90
P/TBV (Quarterly)18.85x
P/B Ratio (Annual)5.41x
Pretax Margin (TTM)-1971.70%
Book Value / Share (Annual)$0.57
Price vs S&P 500 (13W)-20.85%
Beta1.65x
P/FCF (Annual)3.63x
Revenue / Share (TTM)$0.05
ROE (TTM)-101.78%
52-Week Low$1.45
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.40
4.40
4.40
4.40
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACIUAC Immune SA | 66.34x | -86.92% | — | — | $2.98 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
AC Immune SA is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases caused by protein misfolding. The company uses proprietary technology platforms to develop small molecules, antibodies, and vaccines for both therapeutic and diagnostic applications. Its pipeline includes clinical-stage candidates such as Crenezumab and Semorinemab.